Catalent Pharma Solutions won the “Innovation in Process and Formulation Development” category at the annual CPhI Pharma Awards, for its OptiShell softgel technology platform.
Softgel capsules have long been recognized by the pharmaceutical community and patients as effective dosage forms for oral drug delivery. Softgels traditionally use gelatin as the film-forming polymer in the capsule shell, but OptiShell softgel technology uses plant-derived polysaccharides. The different physico-chemical and thermo-mechanical properties of OptiShell capsules allow for encapsulation of a wider range of fill formulation types, including semi-solids formulated at higher temperatures.
Catalent’s OptiShell technology was one of three finalists selected by a panel of pharma industry experts, and the award was presented at a ceremony on October 13th, at CPhI Worldwide.
“OptiShell technology may provide an opportunity for formulators to develop semi-solid, extended release formulations with improved and more consistent therapeutic effectiveness. The ‘hot-filling’ process enables delivery of semi-solid formulations in a patient preferred dose form, while the semi-solid matrix offers extended release profiles that can reduce the maximum API concentration in the bloodstream, decrease the dosing frequency, and, therefore, potentially increase patient adherence,” commented Dr. Aris Gennadios, Catalent’s president of Softgel Technologies, in the press release.
Source: Catalent
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Entering New Domains for 3D Printing of Drug Products
April 6th 20253D printing of personalized medications is currently possible under existing compounding regulations, offering enhanced process control through automation. But new legislation coming in 2025 will allow 3D printing as part of a distributed manufacturing framework.